Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use

Sponsor
Peking University People's Hospital
Study ID
NCT03491371
Status
Completed

Conditions

  • Efficacy
  • Toxicity

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of three Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated sarcoma.

Key Dates

First listed
Apr 9, 2018
Start date
Jun 1, 2015
Status verified
Apr 2018
Primary completion
Dec 31, 2016
Completion
Feb 1, 2017

Study Design

Enrollment
56 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: osteosarcoma
    all patients had been given apatinib alone
  • Experimental: Ewing sarcoma
    Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
  • Experimental: soft tissue sarcoma
    Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
  • Experimental: Chondrosarcoma
    Patients were given apatinib alone

Primary Outcome Measure

objective response rate [ Time Frame: 3 month ]

Related Studies